Lyell Immunopharma (LYEL) to Release Earnings on Wednesday

Lyell Immunopharma (NASDAQ:LYEL) is expected to be posting its quarterly earnings results on Wednesday, February 26th. Analysts expect Lyell Immunopharma to post earnings of ($0.20) per share for the quarter.

Lyell Immunopharma Stock Down 5.1 %

Lyell Immunopharma stock opened at $0.67 on Tuesday. The firm has a 50-day moving average price of $0.61 and a two-hundred day moving average price of $0.98. The firm has a market capitalization of $194.32 million, a price-to-earnings ratio of -0.84 and a beta of -0.35. Lyell Immunopharma has a 52-week low of $0.51 and a 52-week high of $3.26.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the stock. HC Wainwright reissued a “neutral” rating and set a $1.00 target price on shares of Lyell Immunopharma in a research note on Tuesday, November 12th. Bank of America lowered shares of Lyell Immunopharma from a “buy” rating to an “underperform” rating and reduced their target price for the company from $6.00 to $1.00 in a research note on Wednesday, October 30th.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.